[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Spanish Breast Cancer Research Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,77,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609498","impact-of-exercise-on-quality-of-life-of-ebc-patients-on-treatment-with-adjuvant-ai-with-or-without-cdk46-inhibitors-100609498",false,"NCT07215364","Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4\u002F6 Inhibitors","Impact of EXercise on Quality of Life of Early Breast Cancer Patients on Treatment With Adjuvant Aromatase Inhibitors With or Without CDK4\u002F6 Inhibitors. \"The EXAI Study\"","EX-AI","Inclusion Criteria:\n\n1. Written informed consent document (ICD) prior to any specific study procedures, showing patience, willingness and ability to comply with the physical activity program in the experimental group, and scheduled visits and study procedures in both groups.\n2. Patients ≥18 years of age at signing of ICD.\n3. Documented histologically confirmed HR+\u002FHER2- invasive EBC, adequately treated according to standard clinical practice and with absence of any evidence of disease (loco-regional or metastatic at distance).\n\n   HR and HER2 assessments are performed under institutional guidelines.\n   * HR testing should utilize an assay consistent with the most recent American Society of Clinical Oncology (ASCO)\u002F College of American Pathologists (CAP) Guidelines.\n   * HER2 negativity is determined as immunohistochemistry (IHC) score 0\u002F1+ or negative by in situ hybridization (ISH) according to the recommendations of the most recent ASCO\u002FCAP Guidelines.\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2.\n5. Pre-, peri-, and post-menopausal women (as determined by the investigator and according to the institutional guidelines) that have already received between 10 and 18 weeks of an AI (with or without a LHRHa) before the randomization in the study and administered according to local guidelines.\n\n   Note: Patients that are candidate to receive an adjuvant CDK4\u002F6i will only be eligible if the CDK4\u002F6i was initiated at least 6 weeks before the randomization in the study and administered according to local guidelines.\n6. Patients must have undergone adequate (definitive) loco-regional therapy (surgery with or without radiation therapy), with or without neo-\u002Fadjuvant systemic CT.\n7. Patients must have an adequate organ and bone marrow function according to the standard clinical practice and institutional guidelines.\n8. Patients must be able and willing to fill out repeated questionnaires on QoL, pain and fatigue, as well as to adhere to the physical activity program.\n9. Fluent Spanish language skills for the complete comprehension of the questionnaires.\n10. With the consent of the investigator for participation in physical training and considering the medical history of the patient.\n\nExclusion Criteria:\n\n1. Patients have received less than 10 weeks or more than 18 weeks of an AI (with or without a LHRHa) before the randomization in the study.\n2. Patients that are candidate to receive an adjuvant CDK4\u002F6i initiated the treatment less than 6 weeks before the randomization in the study.\n3. Patients have musculoskeletal injuries.\n4. Patients have known significant heart disease (myocardial infarction, unstable angina, congestive heart failure, cardiomyopathy, etc.).\n5. Patients with weight over 150kg.\n6. Patients have any type of illness or mental condition that prevents or compromises the well-being of the patient or compliance with the procedures.\n7. Patients have any cardiovascular contraindication to physical training by the investigator.\n8. Patients have been performing supervised training, either aerobic and\u002For resistance training (at a gym \\[group or individual classes\\] or in a specific sport), at least 2 days per week in the past 6 months.\n9. No access and\u002For unable to manage the website and other digital tools (i.e. applications) for training sessions.","FEMALE","18 Years",{"count":20,"type":21},74,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a national clinical trial (Spain), conducted in approximately 5 sites, where patients who agree to participate will be included in one of two exercise program groups: the experimental group (a combined resistance and aerobic exercise program) and the control group.\n\nThe study will begin with a pilot phase involving approximately 74 patients.\n\nApproximately 37 patients in the experimental group will follow a 6-month training program consisting of exercise sessions three alternate days per week (combining resistance and aerobic exercise).\n\nApproximately 37 patients in the control group will receive standard medical care. These patients will be provided with international exercise guidelines for cancer patients.\n\nPatients will continue with their assigned physical activity intervention until the maximum number of months for the intervention, unacceptable toxicity, discontinuation of hormone therapy, or withdrawal of consent-whichever occurs first.",[27],"Early-stage Breast Cancer",[29,30,31],"early-stage breast cancer (EBC)","HR-positive","HER2-negative","RECRUITING","2026-07-28",{"date":35,"type":36},"2026-07-29","ACTUAL",{"date":38,"type":36},"2026-07-02",{"date":40,"type":21},"2029-03",{"name":42,"class":43},"Spanish Breast Cancer Research Group","OTHER",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100648296","neoagora-exploring-clinical-utility-of-serial-liquid-biopsy-ctdna-in-patients-with-early-stage-breast-cancer-100648296","NCT07718841","neoAGORA: Exploring Clinical Utility of Serial Liquid Biopsy (ctDNA) in Patients With Early-Stage Breast Cancer","neoAGORA: A Prospective Observational Study to Explore the Clinical Utility of Serial Liquid Biopsy in Patients With Early-stage Breast Cancer Receiving Neoadjuvant Therapy.","neoAGORA","Inclusion Criteria:\n\n1. Written informed consent prior to any specific study procedure.\n2. Patients with willingness and ability to comply with study procedures.\n3. Patients (women and men) ≥18 years of age.\n4. Patients with a first diagnosis of the UICC (Union for International Cancer Control) stage I-III primary invasive BC whose tumors are of any of the following subtypes:\n\n   * Luminal: Hormonal Receptor(HR)-positive and HER2-negative.\n   * HER2-positive: HER2-positive regardless of the HR status.\n   * Triple negative: Hormonal Receptor(HR)-negative and HER2-negative. HR and HER2 status should be based on local laboratory determination following the criteria of the American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO\u002FCAP) international guidelines in effect at the time of testing.\n5. Patients that are scheduled to receive NAT as determined by the treating physician according to standard clinical practice.\n6. Archival Formalin-Fixed, Paraffin-Embedded (FFPE) sample of the primary tumor must be available to analyze tumor-informed ctDNA assays.\n\nExclusion Criteria:\n\n1. Patients with stage IV BC.\n2. Patients with previous anti-cancer treatment for the current BC.\n3. Patients with diagnosis of any other invasive malignancy in the 5 prior years, unless the malignancy has been treated with curative intent and is considered at low risk of recurrence, with no evidence of active disease at study entry.\n4. Patients with a diagnosis of bilateral or multifocal breast tumors with different HR or HER2 status.\n5. Patients with any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n6. Patients who are concurrently enrolled in clinical trials.\n7. Females who are pregnant or breastfeeding.","ALL",{"count":55,"type":21},300,"5 Years","OBSERVATIONAL","The goal of this observational study is to explore the utility of analytical techniques that enable the study of small amounts of tumor-derived material circulating in the blood, such as fragments of circulating tumor DNA (also known as ctDNA), cells, or other particles. This type of sample is generally referred to as a liquid biopsy, and its analysis is a minimally invasive test, as it only requires the collection of blood samples. The study includes women and men with early-stage breast cancer (EBC) who are about to start neoadjuvant treatment (treatment given before surgery). The main questions it aims to answer are:\n\n* Can liquid biopsy analyses (ctDNA) provide additional information about the type of tumor before treatment starts?\n* Can these analyses help to detect early whether the tumor is responding to treatment?\n* Can these tests identify if any cancer remains after neoadjuvant treatment or after surgery?\n* Is this information related to the risk of the cancer coming back?\n* Can these analyses, when performed during follow-up, help detect cancer recurrence earlier?\n\nParticipants will:\n\n* Continue receiving standard medical care for their breast cancer, including neoadjuvant therapy and surgery.\n* Provide blood samples at different time points during treatment and follow-up.\n* Provide residual tumor samples from the routine clinical care.",[60],"Early Breast Cancer (EBC)",[62,63,64,65,66],"liquid biopsy","early-stage breast cancer","ctDNA","digital pathology","neoadjuvant therapy (NAT)","NOT_YET_RECRUITING","2026-07-17",{"date":70,"type":36},"2026-07-22",{"date":72,"type":21},"2026-08",{"date":74,"type":21},"2033-08",{"name":42,"class":43},10,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100271959","a-prospective-registry-study-in-patients-with-unresectable-locally-advanced-or-metastatic-breast-cancer-mbc-100271959","NCT02819882","A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)","REGISTEM","Inclusion Criteria:\n\n1. Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016 onwards.\n2. Patients who died are allowed to be included on the study.\n3. Able and willing to provide written informed consent if they are alive.\n4. Age ≥ 18 years.\n5. Availability to medical records access and all data related to the disease management.\n\nExclusion Criteria:\n\nNone",{"count":85,"type":21},1867,"This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.",[88],"Breast Neoplasms",[90,91,92,93],"Unresectable","locally","advanced","metastatic disease","2026-04-01",{"date":96,"type":36},"2026-04-07",{"date":98,"type":36},"2016-08",{"date":100,"type":21},"2026-06",{"name":42,"class":43},40,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100315774","long-term-follow-up-study-of-early-stage-breast-cancer-patients-included-in-geicam-studies-100315774","NCT03390894","Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies","Inclusion Criteria:\n\n* Patients included in neoadjuvant and adjuvant clinical trials with GEICAM's participation. If any of these patients had taken part or is participating in another clinical trial, she\u002Fhe is eligible for this trial and her\u002Fhis information will also be collected.\n* Patients whose death or contact loss has not been previously collected in the databases of the original studies.\n\nExclusion Criteria:\n\n* Patient who were not included in the analyses of the original studies due to non-compliance of the eligibility criteria or the original study informed consent withdrawal.",{"count":110,"type":21},8000,"This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group.\n\nPatients will be included in this study from the moment of completion of the follow-up of the studies of origin and will be followed for approximately 30 years",[113],"Invasive Breast Cancer Early Stages",[115,113,116,117],"Long-term Follow-Up","Previous Neoadjuvant treatment","Previous Adjuvant treatment","2025-05-13",{"date":120,"type":36},"2025-05-14",{"date":122,"type":36},"2018-01-18",{"date":124,"type":21},"2048-01",{"name":42,"class":43},73,""]